News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Sakditad Saowapa: Excited to share our abstract on Proton pump inhibitors in HCC published in JCO
Sakditad Saowapa/X
Jun 5, 2025, 10:57

Sakditad Saowapa: Excited to share our abstract on Proton pump inhibitors in HCC published in JCO

Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:

“Excited to share our abstract published in JCO!

PPIs in HCC = higher risks even after PSM.

  • Mortality: HR 1.18
  • DVT: HR 1.73 | PE: HR 1.96
  • GIB: HR 4.43 | HE: HR 3.26
  • SBP: HR 3.33 | Acute liver failure: HR 3.20
  • Global dataset | 57k+ pts

Honored to be part of this amazing team!”

Proton pump inhibitors and clinical outcomes in hepatocellular carcinoma patients: A propensity score–matched analysis from a global federated dataset.

Authors: Natchaya Polpichai, Sakditad Saowapa, Shu-Yen Chan, Manasawee Tanariyakul, Chanakarn Kanitthamniyom, Andrea Ortiz Maldonado, Chanokporn Puchongmart, Nattanicha Chaisrimaneepan, Miriam Paz Sierra, Phuuwadith Wattanachayakul, Rawipan Uaratanawong, Pharit Siladech, and Lukman Aderoju Tijani.

You can read the full article on Journal of Clinical Oncology.

Sakditad Saowapa: Excited to share our abstract on Proton pump inhibitors in HCC published in JCO

More posts featuring Sakditad Saowapa.

Andrea Ortiz Maldonado cancer Chanakarn Kanitthamniyom Chanokporn Puchongmart fight against cancer Global fight against cancer HCC hepatocellular carcinoma JCO Lukman Aderoju Tijani Manasawee Tanariyakul Miriam Paz Sierra Natchaya Polpichai Nattanicha Chaisrimaneepan OncoDaily Oncology Pharit Siladech Phuuwadith Wattanachayakul PPIs Proton pump inhibitors Rawipan Uaratanawong Sakditad Saowapa Shu-Yen Chan UI Holden Comprehensive Cancer Center
Special Coverage
Blog
Jul 19, 2025, 02:39
Alisher Kakharov: Training at the Prestigious Saint-Louis Hospital in Paris
Blog
Jul 19, 2025, 02:07
Bernard A. Fox: Back in Taiwan - Sharing the Next Frontier in Cancer Immunotherapy at Grand Rounds
Blog
Jul 19, 2025, 02:00
Akash Maniam: How Best to De-Escalate Excellent Responders and Intensify Those Who Don't
Insight
Jul 18, 2025, 21:36
Major disparities in access to Molecular Tumour Boards - Lung Cancer Europe
Oncolibrary
Jul 18, 2025, 21:35
Top 5 AI Tools for Medical Oncologists
Blog
Jul 18, 2025, 20:11
From Lab to Stage: Mastering Research Presentations as a PhD student - Manchester Cancer Research Centre
Blog
Jul 18, 2025, 19:49
Final Call for Discounted Registration to IASLC 2025 World Conference on Lung Cancer
Science
Jul 18, 2025, 19:26
Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer
Blog
Jul 18, 2025, 19:23
Above and Beyond Awards ceremony at The Institute of Cancer Research
Blog
Jul 18, 2025, 19:04
"Belantamab Mafodotin Gives Patients a Chance," Says Diane Moran - International Myeloma Foundation
Insight
Jul 18, 2025, 18:53
Raffaele Colombo: International Nonproprietary Names Proposed List 133 Is Out
Insight
Jul 18, 2025, 18:46
Akhil Santhosh: OrigAMI1 - The Effect of Amivantamab in Previously Treated RAS Wild Colon Cancer